Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Advanced RCC: Brief Overview

March 16th 2022

Tian Zhang, MD, provides an overview of renal cell carcinoma (RCC).

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

March 16th 2022

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Dr. Iacovelli on Next Steps of the ARIES Trial in Urothelial Cancer

March 15th 2022

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Allarity Therapeutics Requests Type C Meeting With FDA to Discuss Dovitinib in Third-Line RCC

March 15th 2022

Allarity Therapeutics, Inc. has filed a formal request with the FDA to hold a Type C meeting where they can discuss possible clinical paths to support the approval of dovitinib in renal cell carcinoma, as well as its DRP-Dovitinib companion diagnostic.

Patient Profile Presentation: A 41-Year-Old Male with Advanced Renal Cell Carcinoma

March 14th 2022

Sumeet Bhatia, MD, presents the patient profile of a 47-year-old male patient with advanced renal cell carcinoma.

Impact of Adjuvant Pembrolizumab Approval on RCC Treatment Landscape

March 14th 2022

Two key opinion leaders review data from a phase 3 clinical trial assessing the use of lenvatinib plus pembrolizumab for the treatment of advanced renal cell carcinoma.

Analysis of Genomic Alterations in Metastases Could Help Inform Treatment in RCC

March 10th 2022

Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.

Adverse Events with IO-TKI Combination Treatment Regimens

March 7th 2022

Two oncologists describe common adverse events seen with I/O–TKI combination treatment regimens for advanced renal cell carcinoma and when they choose to stop the therapy.

Lenvatinib + Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma

March 7th 2022

Dr Eric Jonasch discusses why he chose to treat his patient’s advanced renal cell carcinoma with lenvatinib-pembrolizumab and how he modifies the dosage throughout treatment.

Dr. Choueiri on the Design of KEYNOTE-564 in RCC

March 2nd 2022

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Network Meta-Analysis Evaluates New Decision Algorithm for Fractional Polynomial Selection in First-Line RCC Treatment

February 28th 2022

A clinical algorithm-based approach that was developed to improve fractional polynomial model selection utilized additional criteria based on face validity, predictive accuracy, and expert opinion, which improved the plausibility of survival outcomes in patients with renal cell carcinoma.

Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma

February 28th 2022

Sumeet Bhatia, MD, explains the factors he considers in choosing a treatment for advanced renal cell carcinoma and the role biomarkers have in the process.

Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma

February 28th 2022

Eric Jonasch, MD, presents a real world advanced renal cell carcinoma patient profile and reviews the available first-line IO-TKI combination treatment regimens.

Axitinib/Pembrolizumab Shows Real-World Efficacy in Frontline Advanced RCC

February 27th 2022

A real-world analysis showed that patients with advanced renal cell carcinoma in the United States who received the combination of axitinib and pembrolizumab derived similar efficacy with the regimen as those who had received it in randomized clinical trials.

Real-World Study Shows Fast Uptake of Immunotherapy-Based Combinations in Frontline RCC

February 25th 2022

The FDA approvals of immunotherapy-based combinations as frontline therapy led to a substantial increase in their use in patients with metastatic renal cell carcinoma in the community setting, leading to a greater use of TKI monotherapy as second- and third-line therapies.

Nivolumab/Ipilimumab Shows Superior QOL in Advanced RCC

February 24th 2022

The combination of nivolumab and ipilimumab led to superior quality of life compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma, according to results of a 5-year analysis from the CheckMate 214 trial.

Frontline Checkpoint Inhibition Shows Potential in mRCC With Poor Performance Status

February 22nd 2022

The combinations of nivolumab plus ipilimumab and pembrolizumab plus axitinib demonstrated comparable activity and safety as frontline treatment in patients with metastatic renal cell carcinoma and a performance status of 2 or greater, according to findings from a retrospective study.

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence

February 20th 2022

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

Atezolizumab Fails to Meet PFS End Point in Advanced Penile Squamous Cell Carcinoma

February 20th 2022

Atezolizumab with or without radiotherapy did not demonstrate efficacy in patients with advanced squamous cell carcinoma of the penis.